Best myeloma treatments podcasts we could find (Updated February 2018)
Related podcasts: Myeloma Treatments Prostate Cancer Myeloma Treatment Myeloma Cure Cancer Health and Well-Being Survivorship Resources Cure Multiple Myeloma Myeloma Help Survivor Patient Support Tools Advocacy Medicine Wellness Health  
Myeloma treatments public [search 0]
show episodes
 
C
CureTalks
Monthly
 
CureTalks features leading medical experts in conversation with a panel of patients/advocates about latest research and treatments under development.
 
M
Multiple Myeloma Research Foundation
 
The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers.
 
L
Living With Multiple Myeloma - Cancer Survival Toolbox®
 
This program provides people diagnosed with multiple myeloma - as well as their caregivers, family, and friends - with practical tools you can use in your daily life as you deal with your cancer diagnosis and treatment.
 
Loading …
show series
 
P
Pharmacy Leaders Podcast: Inspiring Leadership Interviews
 
Fourth year student-pharmacist Tola Adebanjo shares her journey through application-based APPEs at Johns Hopkins Hospital in the Clinical Track Student Pharmacist Program, as an APhA Experiential Program Intern, and how she approached the Residency Showcase at ASHP in Orlando. She also outlines the benefits of the three-year PharmD at the Unive ...…
 
This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new endpoints, to novel therapies and imaging. In this video, an overview of these updates are given by Gareth Morgan, MD, FRCP, FRCPath, PhD of UAMS Myeloma Institute, Little Rock, AR, Nina Shah, MD of UCSF Medical Center, San Francisco, CA ...…
 
The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced thought-provoking debate. In this video the main points of debate are discussed by Jeffrey Wolf, MD from the University of California, San Francisco, CA, Roger Owen, MD, MRCP, MRCPath of Leeds Teaching Hospitals NHS Trust, Leeds ...…
 
Guest: Parameswaran Hari, MD Guest: Nina Shah, MD In the age of immunomodulatory agents, proteasome inhibitors, and other novel agents for the treatment of multiple myeloma (MM), the role of autologous hematopoietic stem cell transplantation (ASCT) has become an area of debate. Whereas most oncologists recognize a role for ASCT in the up-front ...…
 
Guest: Parameswaran Hari, MD Guest: Nina Shah, MD In the age of immunomodulatory agents, proteasome inhibitors, and other novel agents for the treatment of multiple myeloma (MM), the role of autologous hematopoietic stem cell transplantation (ASCT) has become an area of debate. Whereas most oncologists recognize a role for ASCT in the up-front ...…
 
Integrating Novel Agents Into Treatment of Relapsed/Refractory Multiple Myeloma: Addressing Current Challenges and Unmet Needs in Brazil
 
When Linda Solomon, a trained medical technologist, saw the results of her routine complete blood count in 2009, she knew it wasn’t good news. Solomon, then 61, was diagnosed with stage III multiple myeloma – and given three years to survive. Several rounds of chemotherapy, two stem cell transplants, and eight years later, Solomon is still here ...…
 
Bloomberg Markets with Carol Massar and Cory Johnson.GUESTS:Dani BurgerStocks ReporterBloomberg NewsDiscussing her story "For Quants, Megacap Tech Rout Looks Like a Systematic Unwind."David WilsonStocks EditorBloomberg NewsDiscussing his "Stock of the Day"Bluebird Bio (BLUE). Bluebird Bio Inc.'s shares fell for the first time in eight days afte ...…
 
Bloomberg Markets with Carol Massar and Cory Johnson.GUESTS:Dani BurgerStocks ReporterBloomberg NewsDiscussing her story "For Quants, Megacap Tech Rout Looks Like a Systematic Unwind."David WilsonStocks EditorBloomberg NewsDiscussing his "Stock of the Day"Bluebird Bio (BLUE). Bluebird Bio Inc.'s shares fell for the first time in eight days afte ...…
 
Bloomberg Markets with Carol Massar and Cory Johnson.GUESTS:Dani BurgerStocks ReporterBloomberg NewsDiscussing her story "For Quants, Megacap Tech Rout Looks Like a Systematic Unwind."David WilsonStocks EditorBloomberg NewsDiscussing his "Stock of the Day"Bluebird Bio (BLUE). Bluebird Bio Inc.'s shares fell for the first time in eight days afte ...…
 
A
All CancerCare Connect Education Workshops
 
* Overview of Transplantation, including Types of Transplantation* Transplantation as a Treatment Option for Multiple Myeloma* General Guidelines for Transplantation* Searching for a Donor* Follow-Up Care* Practical Tips to Manage Post-Treatment Concerns, including Graft vs. Host Disease* The Important Role of Clinical Trials* Communicating wit ...…
 
M
Multiple Myeloma CancerCare Connect Education Workshops
 
* Overview of Transplantation, including Types of Transplantation* Transplantation as a Treatment Option for Multiple Myeloma* General Guidelines for Transplantation* Searching for a Donor* Follow-Up Care* Practical Tips to Manage Post-Treatment Concerns, including Graft vs. Host Disease* The Important Role of Clinical Trials* Communicating wit ...…
 
C
Catalog of Interviews and Bits
 
On Heels on American Society of Clinical OncologyAnnual Meeting (June 2-6) a Look at Latest Advances in Cancer Research and an Inspiring Story The annual meeting of the American Society of Clinical Oncology (ASCO), the largest global cancer conference of the year, brings together the worldâ??s leading cancer researchers to share the latest rese ...…
 
M
Multiple Myeloma CancerCare Connect Education Workshops
 
* Overview of Multiple Myeloma* Current Standard of Care, New Treatment Approaches and the Role of Transplantation* Clinical Trials: How Research Contributes to Your Treatment Options* Practical Tips for Symptom and Pain Management* Reducing Complications of Bone Disease* Physical Activity Concerns, Tips and Guidelines* Communicating with Your ...…
 
A
All CancerCare Connect Education Workshops
 
* Overview of Multiple Myeloma* Current Standard of Care, New Treatment Approaches and the Role of Transplantation* Clinical Trials: How Research Contributes to Your Treatment Options* Practical Tips for Symptom and Pain Management* Reducing Complications of Bone Disease* Physical Activity Concerns, Tips and Guidelines* Communicating with Your ...…
 
Can the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in partnership with Signal Genetics/Quest to determine what is meaninfgul (or not) in determining who is most likely ...…
 
Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody therapies. antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and can ...…
 
T
The Urban Farm Podcast with Greg Peterson
 
216: Emiley Kight on Loving Natural Foods. Making little changes towards more real foods and feeling better. Emiley has always loved food, and wanting to share this passion she dove into a Culinology® degree to explore a role as an R&D chef at SW Minnesota State University. That was until her mom became sick and she put her career on hold to ac ...…
 
Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component parts into either the blood or urine, hence called non-secretory myeloma. Some non-sec ...…
 
Getting back to the beginning of how we started this podcast, it was just Austin and myself covering our entire supplement intake that consists of clinically backed and research health and ergogenic bodybuilding supplements. We could have gone on and on but covered just about everything in this one! Below is some of the literature referenced wi ...…
 
Dr. Gareth Morgan of the UAMS Myeloma Institute joins us to share more about the Myeloma Genome Project, a global effort to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve diagnosis, prognosis and treatment. The project will compile a broad set of genetic data and resulting outcomes ...…
 
In the news this week, the launch of NeuroCDRD – a new initiative to accelerate development of treatments for neuro diseases; OICR researchers invent a new molecular barcode technology; and Aurinia Phramceuticals prices a US$150.5 million public offering of common shares. We have all this and more coming up on Biotechnology Focus Radio. Story 1 ...…
 
Myeloma is the second most common type of blood cancer, accounting for around one percent of blood cancer cases. It develops in plasma cells, white blood cells that grow in bone marrow. Myeloma most often affects the aged — most cases are diagnosed in people age 65 and older. Although myeloma grows within bone, it is not considered bone cancer. ...…
 
Ahead on Biotechnology Focus Radio : Bellus Health back in the game with a new therapeutic asset, BC Cancer Agency scientists make two breakthrough discoveries, and RepliCel Life Sciences gets by with a little help from its friends. We have this and more in store for you on this week’s show. Welcome to another episode of Biotechnology Focus Rad ...…
 
About 10-20% of multiple myeloma patients will develop a condition called amyloidosis during the course of their disease. Amyloidosis is a disease caused by protein buildup in organs such as the heart, kidneys, liver or intestines, leading to organ damage and complications associated with some multiple myeloma treatments. There are three major ...…
 
Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. Despite many new drugs and drug combinations being approved, long term benefits for high risk multiple myeloma patients is less clear. We continue our discussion on high risk myeloma with Dr. Robert Orlowski and talk about the treatmen ...…
 
Coming up on Biotechnology Focus Radio : The future of made-in-Canada CAR-T cells looks bright, Roche Canada and Merck each launch their own individual collaborative cancer research initiatives, and using immunotherapies to kill brain cancer Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you ...…
 
Allogeneic stem cell transplant is rarely used in multiple myeloma treatment, but for younger patients with high-risk myeloma, it could be a highly effective strategy with durable outcomes. Dr. Cristina Gasparetto from Duke University shares the rationale of this approach for a subset of myeloma patients and how improvements in reducing allo si ...…
 
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose therapy and autologous stem cell transplantation continue to remain a backbone of upfront treatment in myeloma. We are talking to Dr. Ravi Vij, about the evolution of myeloma treatments in ...…
 
F
Follicular Lymphoma CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
P
Peripheral T-Cell Lymphoma CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
C
Chronic Myelogenous Leukemia CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
C
Cutaneous T-Cell Lymphoma CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
M
Mantle Cell Lymphoma CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
M
Multiple Myeloma CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
C
Chronic Lymphocytic Leukemia CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
L
Lymphoma CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
L
Leukemia CancerCare Connect Education Workshops
 
* Overview of Blood Cancers* New Research Presented at ASH* Disease-Specific Treatment Updates * Leukemia * Myeloproliferative Neoplasms (MPN) * Lymphoma * Multiple Myeloma* The Role of Clinical Trials* Talking with Your Health Care Team About Your Treatment Options* Quality-of-Life Concerns* Questions for Our Panel of Experts…
 
For the last 50 years, myeloma studies have relied on myeloma progression measurements like complete response (CR) or progression free survival (PFS) to tell whether new treatmets are working (or not). Myeloma patients are now living longer because of new treatment advances, which is a huge blessing. But it is also a challenge for research. If ...…
 
The year 2017 promises to be an exciting one in multiple myeloma research. With so many new types of therapies in the clinic like immunotherapies, specific inhibitors and variations of combinations, the choices are expanding for myeloma patients. Listen to myeloma expert Dr. Robert Z. Orlowski of the MD Anderson Cancer Center as he reviews the ...…
 
At the University of Michigan, Dr. Craig Cole is working on a collaboration with the MMRC to perform genomic sequencing on 500 hundred relapsed and refractory myeloma patients over a two year period. The goal is to share each patient's genomic profile to identify patient-specific treatment options. The study will be open at 11 myeloma academic ...…
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login